CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Gatifloxacin

加替沙星 杂质对照品Gatifloxacin Impurities

35 个杂质条目35 impurity entries

本页汇总 加替沙星 的 35 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 35 impurity reference standards of Gatifloxacin. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 加替沙星(Gatifloxacin)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesFirst derivative synchronous fluorescence spectroscopy for the determination of Gatifloxacin in presence of its oxidative degradation product: Application to pharmaceutical preparation
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2019 · Salama FMM et al.  ·  PMID 30125819  ·  DOI
  2. 杂质研究Impurity studiesDevelopment and validation of an HPLC-UV method for the determination of gatifloxacin in bulk material, pharmaceutical formulations, human plasma and metal complexes
    Pakistan journal of pharmaceutical sciences · 2006 · Sultana N et al.  ·  PMID 17105703
  3. 杂质研究Impurity studies[Impurity analysis and their structure determination of gatifloxacin]
    Yao xue xue bao = Acta pharmaceutica Sinica · 2002 · Zhou HH et al.  ·  PMID 12579807
  4. 分析方法Analytical MethodsSimultaneous determination of gatifloxacin and ambroxol hydrochloride from tablet dosage form using reversed-phase high performance liquid chromatography
    Se pu = Chinese journal of chromatography · 2008 · Shahed M et al.  ·  PMID 18724676  ·  DOI
  5. 分析方法Analytical MethodsDevelopment and validation of stability-indicating high performance liquid chromatography method to analyze gatifloxacin in bulk drug and pharmaceutical preparations
    Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2015 · Aljuffali IA et al.  ·  PMID 25685047  ·  DOI

加替沙星 —— 原料药与杂质对照品Gatifloxacin — drug substance & impurities

共 36 个条目(含原料药本体)36 items incl. the drug substance
Gatifloxacin structure
原料药 APIAPI
加替沙星Gatifloxacin
Gatifloxacin
CAS No.112811-59-3
Chemical FormulaC19H22FN3O4
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 1 structure
1
加替沙星杂质1Gatifloxacin Impurity 1
Gatifloxacin Impurity 1
CAS No.616205-76-6
Chemical FormulaC18H20FN3O4
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 3 structure
3
加替沙星杂质3Gatifloxacin Impurity 3
Gatifloxacin Impurity 3
CAS No.112811-57-1
Chemical FormulaC18H20FN3O4
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 4 structure
4
加替沙星杂质4Gatifloxacin Impurity 4
Gatifloxacin Impurity 4
CAS No.172426-87-8
Chemical FormulaC17H20FN3O4
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 5 structure
5
加替沙星杂质5Gatifloxacin Impurity 5
Gatifloxacin Impurity 5
CAS No.172426-86-7
Chemical FormulaC16H18FN3O4
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 6 structure
6
加替沙星杂质6Gatifloxacin Impurity 6
Gatifloxacin Impurity 6
CAS No.103460-87-3
Chemical FormulaC20H23F2N3O3
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 7 structure
7
加替沙星杂质7Gatifloxacin Impurity 7
Gatifloxacin Impurity 7
CAS No.1215348-50-7
Chemical FormulaC18H20FN3O3·C2HF3O2
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 8 structure
8
加替沙星杂质8Gatifloxacin Impurity 8
Gatifloxacin Impurity 8
CAS No.1029364-59-7
Chemical FormulaC18H22FN3O2
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 9 Monomer structure
9
加替沙星杂质9 单体Gatifloxacin Impurity 9 Monomer
Gatifloxacin Impurity 9 Monomer
CAS No.1029364-65-5
Chemical FormulaC19H22FN3O4
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 9 structure
9
加替沙星杂质9Gatifloxacin Impurity 9
Gatifloxacin Impurity 9
CAS No.1219097-41-2
Chemical FormulaC19H22FN3O4·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 10 structure
10
加替沙星杂质10Gatifloxacin Impurity 10
Gatifloxacin Impurity 10
CAS No.103460-89-5
Chemical FormulaC18H19F2N3O3
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 11 structure
11
加替沙星杂质11Gatifloxacin Impurity 11
Gatifloxacin Impurity 11
CAS No.114213-69-3
Chemical FormulaC20H24FN3O4
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 11 Hydrochloride structure
11
加替沙星杂质11 盐酸盐Gatifloxacin Impurity 11 Hydrochloride
Gatifloxacin Impurity 11 Hydrochloride
CAS No.114213-77-3
Chemical FormulaC20H24FN3O4·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 12 structure
12
加替沙星杂质12Gatifloxacin Impurity 12
Gatifloxacin Impurity 12
CAS No.1335198-95-2
Chemical FormulaC19H22FN3O5
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 13 structure
13
加替沙星杂质13Gatifloxacin Impurity 13
Gatifloxacin Impurity 13
CAS No.1089339-61-6
Chemical FormulaC23H28FN3O5
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 14 structure
14
加替沙星杂质14Gatifloxacin Impurity 14
Gatifloxacin Impurity 14
CAS No.1798008-43-1
Chemical FormulaC19H22FN3O5
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 15 structure
15
加替沙星杂质15Gatifloxacin Impurity 15
Gatifloxacin Impurity 15
CAS No.2327019-81-6
Chemical FormulaC11H10F3NO2
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 16 structure
16
加替沙星杂质16Gatifloxacin Impurity 16
Gatifloxacin Impurity 16
CAS No.55980-34-2
Chemical FormulaC5H9NO2
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 21 structure
21
加替沙星杂质21Gatifloxacin Impurity 21
Gatifloxacin Impurity 21
CAS No.855997-06-7
Chemical FormulaC16H18FN3O4
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 23 structure
23
加替沙星杂质23Gatifloxacin Impurity 23
Gatifloxacin Impurity 23
CAS No.1048972-28-6
Chemical FormulaC21H26FN3O4
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 32 structure
32
加替沙星杂质32Gatifloxacin Impurity 32
Gatifloxacin Impurity 32
CAS No.946578-89-8
Chemical FormulaC17H13BF3NO7
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 35 structure
35
加替沙星杂质35Gatifloxacin Impurity 35
Gatifloxacin Impurity 35
CAS No.1641561-56-9
Chemical FormulaC18H16BF2NO8
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 37 (N1,N2-Dinitroso Gatifloxacin Impurity 59) structure
37
加替沙星杂质37 (N1,N2-二亚硝基加替沙星杂质59)Gatifloxacin Impurity 37 (N1,N2-Dinitroso Gatifloxacin Impurity 59)
Gatifloxacin Impurity 37 (N1,N2-Dinitroso Gatifloxacin Impurity 59)
CAS No.55556-94-0
Chemical FormulaC5H10N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 38 (N-Nitroso Gatifloxacin) structure
38
加替沙星杂质38 (N-亚硝基加替沙星)Gatifloxacin Impurity 38 (N-Nitroso Gatifloxacin)
Gatifloxacin Impurity 38 (N-Nitroso Gatifloxacin)
CAS No.3104323-45-4
Chemical FormulaC19H21FN4O5
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 39 structure
39
加替沙星杂质39Gatifloxacin Impurity 39
Gatifloxacin Impurity 39
CAS No.136897-64-8
Chemical FormulaC9H7F3O3
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 40 (N2-Nitroso Gatifloxacin Impurity 59) structure
40
加替沙星杂质40 (N2-亚硝基加替沙星杂质59)Gatifloxacin Impurity 40 (N2-Nitroso Gatifloxacin Impurity 59)
Gatifloxacin Impurity 40 (N2-Nitroso Gatifloxacin Impurity 59)
CAS No.1172850-85-9
Chemical FormulaC5H11N3O
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 42 structure
42
加替沙星杂质42Gatifloxacin Impurity 42
Gatifloxacin Impurity 42
CAS No.1029364-67-7
Chemical FormulaC20H25N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 44 structure
44
加替沙星杂质44Gatifloxacin Impurity 44
Gatifloxacin Impurity 44
CAS No.36149-51-6
Chemical FormulaC9H17NO2
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 45 structure
45
加替沙星杂质45Gatifloxacin Impurity 45
Gatifloxacin Impurity 45
CAS No.114894-59-6
Chemical FormulaC7H13NO2
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 46 structure
46
加替沙星杂质46Gatifloxacin Impurity 46
Gatifloxacin Impurity 46
CAS No.14205-42-6
Chemical FormulaC8H15NO2
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 47 structure
47
加替沙星杂质47Gatifloxacin Impurity 47
Gatifloxacin Impurity 47
CAS No.1497338-46-1
Chemical FormulaC33H32F2N4O8
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 48 structure
48
加替沙星杂质48Gatifloxacin Impurity 48
Gatifloxacin Impurity 48
CAS No.112811-58-2
Chemical FormulaC19H22FN3O4
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 49 structure
49
加替沙星杂质49Gatifloxacin Impurity 49
Gatifloxacin Impurity 49
CAS No.924-99-2
Chemical FormulaC7H13NO2
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 58 structure
58
加替沙星杂质58Gatifloxacin Impurity 58
Gatifloxacin Impurity 58
CAS No.182868-72-0
Chemical FormulaC20H24FN3O4
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 59 structure
59
加替沙星杂质59Gatifloxacin Impurity 59
Gatifloxacin Impurity 59
CAS No.109-07-9
Chemical FormulaC5H12N2
Purity>95%询价On request
10mg25mg50mg100mg
Gatifloxacin Impurity 64 structure
64
加替沙星杂质64Gatifloxacin Impurity 64
Gatifloxacin Impurity 64
CAS No.1027303-55-4
Chemical FormulaC17H18F3NO4
Purity>95%询价On request
10mg25mg50mg100mg
本品种含亚硝胺类杂质条目。亚硝胺杂质属于 ICH M7 关注的潜在致突变杂质,建议在方法开发中纳入专属性考察。This list includes nitrosamine entries. Nitrosamines are potential mutagenic impurities under ICH M7 and should be covered by a specific method.

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

加替沙星 —— 研究文献与合成路线Gatifloxacin — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 加替沙星 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Gatifloxacin. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. First derivative synchronous fluorescence spectroscopy for the determination of Gatifloxacin in presence of its oxidative degradation product: Application to pharmaceutical preparation
    Salama FMM, Attia KAM, Said RAM, et al. · Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2019 · 被引 5cited 5
  2. Facet-dependent gatifloxacin degradation triggered by manganese dioxide: The dominating role of electron transfer
    Zhao Z, Li Y, Wang G, et al. · Journal of hazardous materials · 2025 · 被引 1cited 1
  3. A digitized impurity database analysis method for determining the impurity profiles of gatifloxacin in bulk materials and injections
    Dousheng Z, Yan C, Yaping L, et al. · Die Pharmazie · 2012
  4. [Impurity analysis and their structure determination of gatifloxacin]
    Zhou HH, Gao SM, Wang EH, et al. · Yao xue xue bao = Acta pharmaceutica Sinica · 2002 · 被引 1cited 1
  5. PROCESS FOR THE PREPARATION OF GATIFLOXACIN AND REGENERATION OF DEGRADATION PRODUCTS
    RUZIC MILOS, RELIC MILENKA, TOMSIC ZDENKA, et al. · 2006
  6. Development and validation of stability-indicating high performance liquid chromatography method to analyze gatifloxacin in bulk drug and pharmaceutical preparations
    Aljuffali IA, Kalam MA, Sultana Y, et al. · Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2015 · 被引 7cited 7

合成与制备工艺专利Synthesis & process patents

  1. OPHTHALMIC GEL OF GATIFLOXACIN AND PREPARATION METHOD THEREOF
    LIU JIDONG, YANG YUCHUN, TANG HAI · 公开号 WO2011063606WO2011063606 · 2011
  2. AQUEOUS LIQUID PREPARATION COMPRISING GATIFLOXACIN
    SAWA SHIROU · 公开号 MX2009003878MX2009003878 · 2009
  3. GATIFLOXACIN-CONTAINING AQUEOUS LIQUID PREPARATION
    SAWA SHIROU · 公开号 US2009247543US2009247543 · 2009
  4. AQUEOUS LIQUID PREPARATION COMPRISING GATIFLOXACIN
    SAWA SHIROU · 公开号 KR20090064572KR20090064572 · 2009
  5. PROCESS FOR PREPARING GATIFLOXACIN
    COSME GOMEZ ANTONIO, VILLASANTE PRIETO JAVIER, PALOMO NICOLAU FRANCISCO · 公开号 WO2005047260WO2005047260 · 2005

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

加替沙星 杂质谱研究要点Gatifloxacin — impurity profiling notes

下面这些是拿到 加替沙星 的 36 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 36 impurity entries for Gatifloxacin, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances